검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NUCALA® |
Overview Company | GSK |
Overview Modality | ANTIBODY |
Overview Target | Nasal Polyps |
Overview Indication | Nasal Polyps |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targeting key T2 inflammatory pathway |
MoA Biomarker | biomarker expression and clinical features |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial.. To evaluate the similarity of BAT2606 and mepolizumab, including pharmacokinetic profiles, immunogenicity, and safety, in healthy Chinese men. This randomized, double-blind, parallel three-arm, … |
Toxicology CRS | 86.4% |
Clinical Primary efficacy | ORR 95.1% |
Clinical ORR | 95.1% |
Clinical Result source | ClinicalTrials.gov NCT03557060 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NUCALA® |
Overview Company | GSK |
Overview Modality | ANTIBODY |
Overview Target | Nasal Polyps |
Overview Indication | Nasal Polyps |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targeting key T2 inflammatory pathway |
MoA Biomarker | biomarker expression and clinical features |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial.. To evaluate the similarity of BAT2606 and mepolizumab, including pharmacokinetic profiles, immunogenicity, and safety, in healthy Chinese men. This randomized, double-blind, parallel three-arm, … |
Toxicology CRS | 86.4% |
Clinical Primary efficacy | ORR 95.1% |
Clinical ORR | 95.1% |
Clinical Result source | ClinicalTrials.gov NCT03557060 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교